Regeneron stock hits record high on positive trial results and FDA approval

From Google: 2024-08-16 11:52:46

Regeneron stock reaches record high of $1179.55, driven by positive clinical trial results and FDA approval for various treatments. Company’s market value surpasses Pfizer and AstraZeneca. Investors bullish on biotech sector amid strong performance. Regeneron remains at forefront of medical innovation with promising pipeline of therapies.



Read more at Google: Regeneron stock soars to all-time high of $1179.55 – Investing.com